PDO Based Drug Sensitive Test in R/M SGC

NCT06686979 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-09-03

No results posted yet for this study

Summary

To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.

Conditions

  • Salivary Gland Cancers
  • Patient Derived Organoid
  • Drug Sensitive Test in Vitro

Interventions

OTHER

No Intervention: Observational Cohort

The patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.

Sponsors & Collaborators

  • Shanghai Cancer Hospital, China

    collaborator OTHER
  • Eye & ENT Hospital of Fudan University

    collaborator OTHER
  • Dongfang Hospital Affiliated to Tongji University

    collaborator OTHER
  • Shandong Cancer Hospital and Institute

    collaborator OTHER
  • Qilu Hospital of Shandong University

    collaborator OTHER
  • Shandong Provincial Hospital

    collaborator OTHER_GOV
  • Hospital of Stomatology, Wuhan University

    collaborator OTHER
  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER
  • Zhejiang University

    collaborator OTHER
  • Sir Run Run Shaw Hospital

    collaborator OTHER
  • Zhejiang Cancer Hospital

    collaborator OTHER
  • Shanghai Huangpu District Central Hospital

    collaborator UNKNOWN
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER
  • Wuhan TongJi Hospital

    collaborator OTHER
  • Zhongnan Hospital

    collaborator OTHER
  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Lai-ping Zhong, MD, PhD · Huashan Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2026-11-30
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686979 on ClinicalTrials.gov